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ABSTRACT
Pancreatic cancer is a leading cause of cancer-related deaths in Western 
societies. This poor prognosis is due to chemotherapeutic drug resistance and 
metastatic spread. Evidence suggests that microtubule proteins namely, β-tubulins 
are dysregulated in tumor cells and are involved in regulating chemosensitivity. 
However, the role of β-tubulins in pancreatic cancer are unknown. We measured 
the expression of different β-tubulin isotypes in pancreatic adenocarcinoma tissue 
and pancreatic cancer cells. Next, we used RNAi to silence βIII-tubulin expression 
in pancreatic cancer cells, and measured cell growth in the absence and presence of 
chemotherapeutic drugs. Finally, we assessed the role of βIII-tubulin in regulating 
tumor growth and metastases using an orthotopic pancreatic cancer mouse model. 
We found that βIII-tubulin is highly expressed in pancreatic adenocarcinoma tissue 
and pancreatic cancer cells. Further, we demonstrated that silencing βIII-tubulin 
expression reduced pancreatic cancer cell growth and tumorigenic potential in the 
absence and presence of chemotherapeutic drugs. Finally, we demonstrated that 
suppression of βIII-tubulin reduced tumor growth and metastases in vivo. Our novel 
data demonstrate that βIII-tubulin is a key player in promoting pancreatic cancer 
growth and survival, and silencing its expression may be a potential therapeutic 
strategy to increase the long-term survival of pancreatic cancer patients.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is a 
devastating disease that ranks as the fourth leading 
cause of cancer-related death in Western societies, with 
a 5-year survival rate of 6-7% [1-5]. This poor prognosis 
is due to PDA’s propensity to acquire resistance to 
chemotherapeutic agents and metastasize [8, 9]. The 
result is that our current chemotherapeutic treatments 
only extend patient survival by ∼8–16 weeks [10]. These 
statistics highlight the imperative to identify effective 
therapeutic targets for this devastating disease. 
The tubulin/microtubule network is recognized as a 
key player in cancer chemoresistance [11]. Microtubules 
are tube-like assemblies of α-and β-tubulin heterodimers, 
that form part of the cell cytoskeleton and play critical 
roles in regulating mitosis and intracellular transport [11]. 
β-tubulin has seven different isotypes (βI, βII, βIII, βIVa, 
βIVb, βV, βVI) that exhibit distinct tissue expression 
profiles [11]. Notably, all of the β-tubulin isotypes share 
a high degree of homology and are distinguished by 
their unique carboxy terminal tail which is subject to 
post-translational modifications [11]. The importance 
of microtubules as therapeutic targets for cancer is 
highlighted by the clinical use of tubulin binding agents 
(TBAs) which target β-tubulin. At high concentrations 
these agents induce mitotic arrest and cause cell death 
[12]. However, therapeutic applications of TBAs are 
often marred by resistance, which is often correlated to 
differential expression of specific β-tubulin isotypes [11]. 
Clinical studies have reported high expression of βIII-
tubulin in several cancers including lung, breast, prostate, 
gastric and melanoma [13-18]. Under non-pathological 
conditions βIII-tubulin expression is primarily restricted 
to neurons, and sertoli cells in the testis, and at low levels 
in other tissues [19, 20]. Interestingly, its upregulation in 
cancer cells has been correlated to decreased progression-
free or overall survival and resistance to chemotherapeutic 
agents [21]. Functional studies have confirmed the 
importance of βIII-tubulin in regulating sensitivity to 
chemotherapeutic agents in non-small cell lung cancer 
(NSCLC), ovarian cancer and prostate cancer cells [22-
25]. 
Up-regulation of βIII-tubulin has been observed in 
advanced PDA patient tissue specimens and cell lines [26]. 
Interestingly, aberrant βIII-tubulin expression in PDA 
cells was associated with activation of kRAS (oncogene 
commonly associated with PDA) and appeared to be 
progressively upregulated in pancreatic intraepithelial 
neoplasias (PanIN) 1 to 3, the precursor lesions of PDA 
[26]. Despite this strong correlation, no functional role 
for βIII-tubulin has been established in pancreatic cancer. 
Using a gene-silencing approach we silenced βIII-tubulin 
expression in pancreatic cancer cells and determined 
its role in regulating chemosensitivity, cell growth, 
tumorigenesis and metastases. We report for the first time 
that silencing βIII-tubulin in pancreatic cancer cells in 
vitro 1) decreases clonogenicity; 2) decreases anchorage-
dependent and independent proliferation; 3) increases 
apoptosis and anoikis; and 4) increases sensitivity to 
chemotherapy drugs including gemcitabine and the TBAs 
paclitaxel and vincristine. Notably, we demonstrate the 
importance of βIII-tubulin in regulating tumor growth and 
metastases in a clinically-relevant orthotopic pancreatic 
cancer mouse model. 
RESULTS
βIII-tubulin is expressed in human pancreatic 
tumor cells
βIII-tubulin was expressed at high levels in 
pancreatic tumor cells, while absent in the acinar and 
normal ductal cells in PDA tissue (Figure 1A). To 
determine whether the expression pattern was specific 
to βIII-tubulin, we also examined the levels of another 
β-tubulin isotype, βII-tubulin, which has been shown to be 
differentially expressed in tumor cells [27-29]. It too was 
present at high levels in pancreatic tumor cells, however 
in contrast to βIII-tubulin, it was also present in acinar and 
normal ductal cells (Supplementary Figure 1). Next, we 
measured βIII-tubulin expression by western blotting in 
cell lysates from 3 different pancreatic cancer cell lines 
derived from primary (MiaPaCa-2, Panc-1) and metastatic 
(HPAF-II) sites. βIII-tubulin levels were significantly 
higher in all 3 pancreatic cancer cell lines compared 
to normal non-tumorigenic human pancreatic ductal 
epithelial (HPDE) cells (Figure 1B). βII-tubulin was also 
higher in 2/3 pancreatic cancer cell lines (MiaPaCa-2 and 
Panc-1) compared to HPDE cells (Figure 1B). Notably, βI-
tubulin, which is constitutively expressed in most tissues, 
was expressed at similar levels in the pancreatic cancer 
cell lines and the normal HPDE cells (Figure 1B). 
Potent and specific knockdown of βIII-tubulin in 
pancreatic cancer cells
To examine whether βIII-tubulin could be 
suppressed in pancreatic cancer cells, we transfected 
two-independent pancreatic cancer cell lines (MiaPaCa-2 
and HPAF-II) with βIII-tubulin siRNA. 48h and 72h 
post transfection, βIII-tubulin expression was measured. 
Knockdown of βIII-tubulin was observed at the gene 
level in both cell lines (MiaPaCa-2, 84.4 ± 2.6% knock-
down; HPAF-II, 76.8 ± 1.1% knock-down relative to 
control-siRNA; 72h post-transfection) (Figure 2A and B). 
This correlated to knockdown (>90%) of βIII-tubulin at 
the protein level (Figure 2A and B). Knockdown of βII-
tubulin was also observed when pancreatic cancer cells 
(MiaPaCa-2 and HPAF-II) were treated with βII-tubulin 
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siRNA (Supplementary Figure 2). 
To confirm that knockdown of βIII-tubulin was 
specific and did not cause compensational changes in the 
expression of other major β-tubulin isotypes, MiaPaCa-2 
cells were transfected with βIII-tubulin siRNA and 72h 
later the levels of total β-tubulin, βI-tubulin and βII-
tubulin were measured. No change in the expression of 
the above β-tubulins were observed following βIII-tubulin 
silencing (Figure 2C). 
βIII-tubulin silencing decreases clonogenicity and 
increases sensitivity to chemotherapeutic drugs in 
pancreatic cancer cells
To establish the functional role of βIII-tubulin in 
pancreatic cancer, we determined the effect of silencing 
βIII-tubulin expression on the clonogenic potential of 
pancreatic cancer cells in the absence or presence of 
chemotherapeutic drugs. Silencing βIII-tubulin in the 
absence of chemotherapy significantly reduced the ability 
of pancreatic cancer cells (MiaPaCa-2 and HPAF-II) to 
form colonies compared to controls (Figures 3A and 3D). 
Moreover, the number of pancreatic cancer cell colonies 
was further decreased in the presence of the chemotherapy 
agents paclitaxel, vincristine, and gemcitabine (used 
in the first-line treatment of pancreatic cancer) when 
compared to controls (ns-siRNA) (Figures 3A-3F). In 
contrast, silencing βII-tubulin had no effect on pancreatic 
cancer cell colony formation in the absence or presence 
of chemotherapy drugs (Supplementary Figure 3A-3F). 
Silencing βIII-tubulin or βII-tubulin had no effect on cell 
viability or growth of normal non-tumorigenic HPDE cells 
(Supplementary Figure 4A and B). This suggests that βIII-
FIGURE 1: βIII-tubulin expression in PDA patient tissue and PDA cell lines. A) Immunohistochemistry for βIII-tubulin in a 
representative human PDA tissue specimen. Panels show tissue stained with either isotype control antibody (i) or βIII-tubulin antibody (ii-
iv). The isotype control was negative and tumor elements had strong immunoreactivity for βIII-tubulin. Panel iv demonstrates an absence 
of βIII-tubulin staining in normal acinar cells (region marked by dashed border) and normal ductal cells (arrow) away from the tumor. 
B) Western blot analysis for βI-, βII-and βIII-tubulin in protein extracts from pancreatic cancer cell lines (MIA Paca-2, Panc-1, HPAF-II) 
versus normal human non-tumorigenic pancreatic ductal epithelial cells (HPDE). GAPDH was used as a loading control. C) Densitometry 
analysis of βIII-tubulin expression normalized to GAPDH expression demonstrates that βIII-tubulin is significantly increased in all 3 
pancreatic cancer cell lines compared to HPDE cells (*p<0.05; n=3).
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tubulin may have a specific functional role in pancreatic 
cancer cells. 
To determine whether silencing βIII-tubulin would 
affect the structure of the microtubule cytoskeleton of 
pancreatic cancer cells, MiaPaCa-2 and HPAF-II cells 
were transfected with βIII-tubulin- or control siRNA, and 
stained with fluorescent antibodies against total α-tubulin 
(red) to visualize the microtubule cytoskeleton and βIII-
tubulin (green). Suppression of βIII-tubulin, did not affect 
the structural integrity of the microtubule cytoskeleton 
(Figure 4A and 4B). 
Next, we examined whether the increased 
sensitivity of pancreatic cancer cells to TBAs (paclitaxel 
and vincristine) following silencing of βIII-tubulin was 
due to increased disruption of mitosis. MiaPaCa-2 and 
HPAF-II cells were transfected with βIII-tubulin siRNA 
and then treated with increasing concentrations of 
paclitaxel (microtubule-stabilizing agent) or vincristine 
(microtubule-destabilizing agent) and their cell cycle 
measured. We observed increased accumulation of both 
control (ns-siRNA) and βIII-tubulin-siRNA treated cells 
in G2/M phase, along with a corresponding decrease in 
G0/G1 phase with increasing concentrations of paclitaxel 
(Figure 4C) and vincristine (Figure 4D). However, βIII-
tubulin knockdown did not markedly affect cell cycle 
distribution, relative to controls (ns-siRNA; Figure 4C-
D), suggesting that the decreased clonogenic potential of 
βIII-tubulin knockdown cells in the absence or presence of 
TBAs was not due to enhanced disruption of the cell cycle. 
FIGURE 2: βIII-tubulin silencing in pancreatic cancer cell lines. A) Top panel, Western blot analysis of βIII-tubulin silencing 
in protein extracts from MiaPaCa-2 cells. Cell lysates were harvested from cells 48h or 72h after transfection with mock, control siRNA 
(ns-siRNA), or βIII-tubulin siRNA (βIII-Tub siRNA). GAPDH was used as a loading control. Bottom graph, real-time PCR analysis of 
βIII-tubulin silencing in MiaPaCa-2 cells. RNA was harvested from cells 48h or 72h after transfection with mock, ns-siRNA, or βIII-tub 
siRNA. βIII-tubulin mRNA levels were normalized to 18S mRNA. B) as per A, except cell extracts were obtained from HPAF-II cells. 
Asterisks indicate significance (** p≤0.01, ** p≤0.01; n=3). C) Representative Western blots for βI-, βII-, βIII-tubulin and total tubulin in 
protein extracts from MiaPaCa-2 cells transfected with mock, ns-siRNA, or βIII-Tub siRNA (n=3). GAPDH was used as a loading control.
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βIII-tubulin silencing induces apoptosis in 
pancreatic cancer cells
To investigate whether apoptosis was responsible 
for the reduction in the number of pancreatic cancer cell 
colonies, MiaPaCa-2 cells were transfected with βIII-
tubulin or control siRNA (ns-siRNA) and then treated with 
or without chemotherapy drugs. βIII-tubulin suppression 
in pancreatic cancer cells induced a marked increase in 
apoptosis (Annexin V and 7AAD) in the absence of 
chemotherapy drugs (Figure 5A-F). This was echoed 
by a significant increase in caspase 3/7 activity, in βIII-
tubulin knockdown cells (Figure 5D-F). Furthermore, 
the increase in apoptosis was sustained in the presence of 
chemotherapy drugs (Figure 5D-F). These data suggest 
that the decreased clonogenic potential in pancreatic 
cancer cells is mediated via increased apoptosis. To the 
best of our knowledge this is the first report to demonstrate 
a role for βIII-tubulin in regulating cell survival in tumor 
cells in the absence of chemical and /or environmental 
stress. 
βIII-tubulin silencing reduces the tumorigenic 
potential of pancreatic cancer cells
Our drug-clonogenic and apoptosis results suggested 
that βIII-tubulin might be playing a survival role in 
pancreatic cancer cells. Therefore, we investigated the 
effect of βIII-tubulin suppression on pancreatic cancer 
cell anchorage-dependent and -independent growth, as 
well as anoikis (anchorage-independent programmed 
cell death). Tumor cells with high tumorigenic and 
metastatic potential have acquired mechanisms to 
grow and survive under both anchorage-dependent and 
independent conditions, and develop mechanisms to 
resist anoikis. First, anchorage-dependent cell growth was 
FIGURE 3: The effect of βIII-tubulin silencing on pancreatic cancer cell clonogenic capacity. A-C) Bars represent the 
number of MiaPaCa-2 colonies (mean±s.e.m. as a % of mock) that formed from low density seeding following transfection with mock, 
control siRNA (ns-siRNA), or βIII-tubulin siRNA (βIII-Tub siRNA) and 72h culture in titrations of Gemcitabine (A), Paclitaxel (B) or 
Vincristine (C). D-F) as per A-C, except experiments were carried out with HPAF-II cells. Asterisks indicate significance relative to ns-
siRNA of the same drug dose (*** p≤0.001, **** p≤0.0001; n=5). Hashes indicate significance relative to 0 nM drug concentration of the 
same siRNA (# p≤0.05, ## p≤0.01, #### p≤0.0001; n=5). 
Oncotarget2240www.impactjournals.com/oncotarget
measured in real-time using the xCELLigence platform. 
Consistent with our drug-clonogenic results, we observed 
significantly reduced cell proliferation in MiaPaCa-2 cells 
transfected with βIII-tubulin siRNA relative to controls 
(ns-siRNA) over 48h (Figure 6A). Next, we assessed the 
effects of βIII-tubulin knockdown on pancreatic cancer 
cell anchorage-independent growth. MiaPaCa-2 and 
HPAF-II cells were transfected with βIII-tubulin siRNA 
FIGURE 4: The effect of βIII-tubulin silencing on pancreatic cancer cell morphology and cell cycle. A) Confocal 
microscopy for α-tubulin and βIII-tubulin in MiaPaCa-2 cells transfected with control siRNA (ns-siRNA) (top panels) or βIII-tubulin 
siRNA (βIII-Tub siRNA; bottom panels). Overlaid fluorescence images are shown in the far right panel of each row. B) as per A, except 
HPAF-II cells were used. C-D) Cell cycle distribution was analyzed by propidium iodide staining and flow cytometry. Bars represent % of 
MiaPaCa-2 cells in G0/G1-phase, S-phase, or G2/M-phase (mean±s.e.m.). 72h post-transfection with either ns-siRNA or βIII-Tub siRNA 
cells were incubated for eight hours with Paclitaxel (C) or Vincristine (D). Asterisks indicate significance relative to the no drug control of 
the same siRNA (* p≤0.05, *** p≤0.001, **** p≤0.0001; n=5). 
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or control siRNA (ns-siRNA) and then grown in soft-
agar for 14 days. Knockdown of βIII-tubulin significantly 
reduced the number of cell colonies formed (Figure 6B 
and 6C). Finally, to investigate whether the reduction 
in cell colonies was in part due to anoikis, MiaPaCa-2 
cells transfected with control or βIII-tubulin siRNA were 
cultured in suspension for 48h. We observed a significant 
increase in the apoptotic fraction of MiaPaCa-2 cells with 
knockdown of βIII-tubulin (Figure 6D). Collectively, these 
results provide strong evidence that βIII-tubulin plays an 
important role in promoting the growth and metastatic 
potential of pancreatic cancer cells. 
Stable suppression of βIII-tubulin reduces tumor 
growth and metastases in an orthotopic murine 
model of pancreatic cancer
To extend our findings in vivo, we generated 
MiaPaCa-2 cells that stably expressed luciferase and a 
βIII-tubulin shRNA construct. Cells stably expressing 
the same construct but with a non-functional shRNA (ns-
shRNA) served as controls. These cells possessed potent 
knockdown of βIII-tubulin compared to control shRNA 
cells (Supplementary Figure 5A and 5B). Notably, cells 
with stable suppression of βIII-tubulin had a significant 
FIGURE 5: βIII-tubulin silencing induces apoptosis in MiaPaCa-2 cells. A-C) MiaPaCa-2 cells transfected with control siRNA 
(ns-siRNA) or βIII-tubulin siRNA (βIII-Tub siRNA). 48h post-transfection cells were cultured in titrations of Gemcitabine (A), Paclitaxel 
(B), or Vincristine (C) for 24h. Bars represent the fraction of total MiaPaCa-2 cells that are apoptotic (mean+s.e.m. as a % of ns-siRNA no 
drug control) as determined by Annexin V and 7AAD staining. Asterisks indicate significance relative to ns-siRNA controls of the same 
drug dose (* p≤0.05, ** p≤0.01, *** p≤0.001; n=3-4). D-F) MiaPaCa-2 cells transfected with ns-siRNA or βIII-Tub siRNA were cultured 
in titrations of Gemcitabine (D), Paclitaxel (E), or Vincristine (F) for 24h. Bars represent caspase 3/7 activity (mean±s.e.m. as a % of ns-
siRNA no drug control). Asterisks indicate significance relative to ns-siRNA controls of the same drug dose (* p≤0.05, ** p≤0.01, *** 
p≤0.001; n=4-5).
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decrease in anchorage-independent growth when 
compared to controls (ns-shRNA) (Figure 7A). These 
results concurred with our data using transient knockdown 
of βIII-tubulin (Figure 6B). Cells were implanted into the 
pancreas of mice, and allowed to grow for 8 weeks before 
tumors along with the spleen, liver, kidneys, intestines, 
and heart/lungs were harvested together with any lymph 
nodes that exhibited signs of metastases. βIII-tubulin 
knockdown in the tumors (8 weeks post implantation) 
containing βIII-tubulin shRNA was confirmed (Figures 
7B-7D). Pancreatic tumors expressing βIII-tubulin shRNA 
had significantly reduced tumor volume relative to control 
shRNA tumors (Control: 145.0 ± 30.5 mm3, βIII-Tubulin 
shRNA: 80.6 ± 21.9 mm3, p<0.05; Figure 8A-B). The 
incidence of metastases was reduced by 30% in mice 
with tumors expressing βIII-tubulin shRNA (4/10 mice 
had metastases) versus tumors expressing control shRNA 
(7/10 mice had metastases). Metastases that were detected 
by ex vivo imaging of individual organs on a Xenogen 
IVIS platform (Supplementary Figure 6A) were found to 
be reduced by 62.5% in the βIII-tubulin shRNA pancreatic 
tumors, relative to controls (Figure 8C-D). Metastases 
detected by ex vivo imaging were confirmed by histology 
(Supplementary Figure 6B) and immunohistochemistry 
(Supplementary Figure 6C).
DISCUSSION
Pancreatic cancer is chemoresistant and metastatic, 
making this a lethal cancer. There is mounting evidence to 
FIGURE 6: βIII-tubulin silencing reduces both anchorage dependent and independent pancreatic cancer cell growth. 
A) xCelligence assay of MiaPaCa-2 cells transfected with ns-siRNA or βIII-tubulin siRNA (βIII-Tub siRNA). 72h post-transfection cells 
were seeded into xCelligence plates. Circles represent cell index (mean±s.e.m.) at hourly time points, and are directly related to cell 
number. Asterisks indicate significance (*** p≤0.001; n=3). B) MiaPaCa-2 cells transfected with mock, ns-siRNA or βIII-Tubulin siRNA 
were embedded in soft-agarose at 48h post-transfection and allowed to form colonies. Bars represent the number of colonies that formed 
(mean+s.e.m. as a % of mock). Asterisks indicate significance (*p≤0.05; n=3). C) As per B, except experiments were carried out with 
HPAF-II cells (* p≤0.05; n=3). D) MiaPaCa-2 cells were transfected with ns-siRNA or βIII-tubulin siRNA and 24h post-transfection cells 
were cultured under anchorage independent conditions for a further 48h (wells coated with Poly-HEMA). Bars represent the apoptotic 
fraction determined by Annexin V and 7AAD staining (mean±s.e.m.). Asterisks indicate significance (*** p≤0.001; n=3).
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show that βIII-tubulin is dysregulated in tumor cells, and 
its increased expression is correlated to poor survival [30-
33]. However, the role of βIII-tubulin in pancreatic cancer 
is unknown. We report novel functions for βIII-tubulin 
in regulating pancreatic cancer cell growth and survival 
in the absence and presence of chemotherapeutic drugs. 
In addition, we demonstrate that silencing βIII-tubulin 
expression in pancreatic cancer cells results in reduced 
tumor growth and metastases in vivo. 
In health, βIII-tubulin expression is restricted 
to neuronal tissue and testicular sertoli cells [19, 20]. 
However, clinical studies report high levels of βIII-
tubulin in different tumors including breast, lung, ovarian, 
gastric and melanoma [13-18]. Recently, high βIII-tubulin 
expression was reported in prostate cancer, and was linked 
to high Gleason grade, advanced tumor stage and local 
FIGURE 7: βIII-tubulin shRNA expressing MiaPaCa-2 cells have reduced anchorage-independent growth and potent 
long-term βIII-tubulin knockdown in vivo. A) MiaPaCa-2 cells stably expressing βIII-Tubulin (βIII-Tub) or control shRNA (ns-
shRNA) were embedded in soft-agarose and allowed to form colonies. Bars represent the number of colonies that formed (* p≤0.05; 
n=3). Representative micrographs showing colony formation in MiaPaca-2 cells stably expressing control (ns-shRNA) or βIII-Tubulin 
(βIII-Tub) shRNA. B) Western blot for βIII-tubulin in protein extracts from non-silencing shRNA (ns-shRNA) and βIII-Tubulin shRNA 
(βIII-Tub shRNA) tumors after eight weeks of in vivo growth. GAPDH was used as a loading control. C) Densitometry analysis of βIII-
tubulin expression normalized to GAPDH expression demonstrates that βIII-tubulin is significantly decreased in pancreatic tumors stably 
expressing βIII-tubulin shRNA compared to control (ns-shRNA) expressing tumors (*p<0.05; n=7). D) Immunohistochemistry for βIII-
tubulin in tissue sections from primary tumors expressing (i-v) ns-shRNA or (vi-ix) βIII-Tubulin shRNA.
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metastases [31]. In this study we demonstrated that βIII-
tubulin was expressed at high levels in pancreatic tumor 
cells, while absent in the acinar and normal pancreatic 
ducts in tissue specimens collected after surgical resection. 
We also showed increased expression of βIII-tubulin in 
pancreatic cancer cell lines compared to primary cultures 
of HPDE cells. Our results are in accordance with a study 
by Lee et al. [26], which reported βIII-tubulin expression 
in advanced PDA tissue samples. However, prior to the 
present study, there have been no studies to elucidate its 
functional role. 
Using RNAi we demonstrated that silencing βIII-
tubulin in pancreatic cancer cells reduced their ability to 
form cell colonies. Moreover, the number of colonies was 
further reduced when the cells were treated with different 
chemotherapy drugs including, the anti-metabolite 
gemcitabine (used in the first-line treatment of pancreatic 
cancer) and the TBAs paclitaxel and vincristine [albumin 
bound paclitaxel (Abraxane) is now used in the clinic 
to treat pancreatic cancer and vincristine while not a 
pancreatic cancer treatment, was used in this study to 
help delineate βIII-tubulin’s function]. Knockdown of 
βII-tubulin, which was also overexpressed in pancreatic 
cancer cells, had no effect on the clonogenic potential 
of pancreatic cancer cells in the absence or presence of 
chemotherapy drugs. This result is in contrast to a previous 
study in NSCLC cells which showed that silencing βII-
tubulin expression increased sensitivity to Vinca alkaloids 
(25). Therefore, it is possible that the ability of pancreatic 
cancer cells to form colonies in the absence or presence 
FIGURE 8: The effect of βIII-tubulin silencing on orthotopic tumor growth and metastases. A) Representative 
photomicrographs of primary tumors expressing control (ns-shRNA) or βIII-tubulin (βIII-Tub) shRNA eight weeks post-implantation (n=4 
individual mice per group). B) Bars represent tumor volume (mean±s.e.m.) of primary pancreatic tumors eight weeks post-implantation. 
Asterisks indicate significance (* p≤0.05; n=9 for ns-shRNA and n=10 for βIII-tubulin shRNA). C) Bars represent the number of metastatic 
sites per mouse (mean±s.e.m.) eight weeks post-implantation. Asterisks indicate significance (* p≤0.05). D) Table showing the total number 
of metastases detected in each organ for ns-shRNA and βIII-Tub shRNA tumors.
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of chemotherapy drugs may be β-tubulin isotype specific. 
Moreover, βIII-tubulin appears to have a tumor cell-
specific effect as silencing its expression in normal HPDE 
cells had no effect on their cell viability or proliferation. 
A role for β-tubulin isotypes in regulating 
chemosensitivity in tumor cells has been described. Gan 
et al. [22] showed that silencing βIII-tubulin in NSCLC 
cells reduced their clonogenic capacity in the presence 
of chemotherapy. This finding was extended to an in 
vivo setting by McCarroll et al. [24], which reported 
that stable suppression of βIII-tubulin in NSCLC cells 
increased survival in mice when treated with cisplatin. 
More recently, βIII-tubulin was shown to be involved 
in regulating docetaxel sensitivity in castrate-resistant 
prostate cancer cells [31]. Interestingly, Gan et al. [28] 
reported that suppression of βII- or βIVb-tubulin in 
NSCLC cells increased sensitivity to only one class of 
chemotherapy drugs known as Vinca Alkaloids. These 
studies reinforce the concept that individual β-tubulin 
isotypes may have specific functional roles in tumor cells, 
with βIII-tubulin appearing to be important in regulating 
sensitivity to broad classes of chemotherapy drugs. 
However, despite the increasing number of studies that 
highlight the importance of βIII-tubulin in tumor cells, its 
mode of action has yet to be fully determined. 
In an attempt to understand how βIII-tubulin is 
exerting its effect on pancreatic cancer cells we first 
examined whether silencing its expression influenced the 
structural integrity of the microtubule cytoskeleton, given 
the importance of microtubule proteins in regulating 
the shape and structure of cells. Silencing βIII-tubulin 
expression in pancreatic cancer cells had no effect on 
the structure of the microtubule cytoskeleton. Next, we 
assessed whether silencing βIII-tubulin impacted the 
cell cycle given the importance of microtubule proteins 
in regulating mitosis. No significant effect on the cell 
cycle was observed. We also showed that silencing βIII-
tubulin did not potentiate the anti-mitotic effect of TBAs 
in pancreatic cancer cells. Together, these results indicate 
that the observed decrease in the clonogenic potential of 
pancreatic cancer cells with suppressed βIII-tubulin in the 
absence or presence of chemotherapeutic drugs does not 
involve modulation of the microtubule cytoskeleton or the 
cell cycle. 
Finally, to determine whether this decrease in 
the clonogenic potential of pancreatic cancer cells with 
suppressed βIII-tubulin was due to increased sensitivity 
to cell death, we measured apoptosis in pancreatic cancer 
cells. We demonstrated that silencing βIII-tubulin induced 
cell death in pancreatic cancer cells which was sustained 
in the presence of chemotherapy. It appeared that the 
intrinsic apoptotic pathway was involved as evidenced 
by increased caspase 3/7 activity. This is the first study to 
report a significant induction of apoptosis in tumor cells 
with suppressed βIII-tubulin in the absence of cellular 
stress. Previously, induction of apoptosis in tumor cells 
with knockdown of βIII-tubulin was observed only when 
cells were treated with chemotherapeutic drugs [22, 
24]. Therefore, it appears that pancreatic cancer cells 
are highly sensitive to suppression of βIII-tubulin, and 
that this protein may provide these cells with a survival 
advantage. Indeed, evidence in other cell types suggest 
that βIII-tubulin may be part of a cell survival pathway. 
For instance, its expression levels can be modulated by 
different types of cell stress. In two separate studies, 
Raspaglio et al [34, 35] demonstrated increased βIII-
tubulin expression in ovarian cancer cells exposed to 
hypoxia or nutrient deprivation. Under these conditions 
βIII-tubulin was shown to bind to important signaling 
proteins such as pro-survival kinase PIM1 [36]. This 
protein kinase is involved in promoting chemoresistance, 
and its expression levels have been correlated with 
aggressive disease in pancreatic cancer [37, 38]. 
Therefore, it is possible that the increased levels of βIII-
tubulin allow for PIM1 to exert its pro-survival effect in 
pancreatic cancer cells. In addition, a glycosylated and 
phosphorylated form of βIII-tubulin has been identified in 
the mitochondria of cancer cells [39]. It may be possible 
that βIII-tubulin is involved in modulating apoptosis via 
the mitochondria. Studies aimed at understanding how 
βIII-tubulin hypersensitizes pancreatic cancer cells to 
apoptosis are under investigation in our laboratory. 
To determine whether suppression of βIII-tubulin 
would affect the tumorigenic and metastatic potential 
of pancreatic cancer cells, we silenced βIII-tubulin 
expression in pancreatic cancer cells and measured 
anchorage-dependent and independent-cell growth. 
Knockdown of βIII-tubulin resulted in a significant 
reduction in anchorage-dependent and independent 
growth. The decrease in anchorage-independent cell 
growth was associated with increased anoikis (anchorage-
independent apoptosis), reinforcing the link between βIII-
tubulin silencing and induction of apoptosis in pancreatic 
cancer cells. Indeed, tumor cells with high metastatic 
potential have developed mechanisms of resistance to 
this form of apoptosis [40]. To establish whether the 
decreased tumorigenic potential in pancreatic cancer cells 
with suppressed βIII-tubulin would translate in vivo, we 
generated pancreatic cancer cells which stably expressed 
βIII-tubulin shRNA. We showed for the first time that 
when these cells were implanted into the pancreas of 
mice there was decreased primary tumor growth and 
metastases. Together, these data demonstrate that βIII-
tubulin is important in providing pancreatic cancer cells 
with a key survival advantage, thus allowing them to grow 
and metastasize. 
Collectively, this work has identified a novel role 
for βIII-tubulin in promoting pancreatic cancer growth 
and survival. Identification of βIII-tubulin as a therapeutic 
target has the potential to refine personalized medicine 
for patients with this malignancy. The relatively limited 
impact of chemotherapy in this malignancy does require 
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identification of agents with alternative anti-tumor 
activity. Drugs targeting this system would be predicted 
to have limited effects on normal tissues. Therefore 
they lend themselves to prolonged use, such as in the 
adjuvant setting. In particular the anti-metastatic effect 
shown in vivo encourages exploration of their use in the 
adjuvant setting and in conjunction with or sequential to 
chemotherapy. 
MATERIALS AND METHODS
Cell culture
Human pancreatic cancer cells (MiaPaCa-2, Panc-
1 and HPAF-II) were obtained from ATCC and cultured 
as described [41]. Normal Human Pancreatic Ductal 
Epithelial (HPDE) cells (a kind gift from Ming Tsao, 
Ontario Cancer Institute) were grown in Keratinocyte-
serum-free (KSF) medium supplemented with 50 mg/
ml bovine pituitary extract (BPE) and 5 ng/ml epidermal 
growth factor (EGF) as described [42]. 
Immunohistochemistry 
Human PDA tissue specimens were collected by 
surgical removal. The use of these sections was approved 
by UNSW Human Research Ethics Committee (HCEC# 
HC14039). Immunohistochemistry was performed on 
paraffin-embedded human or mouse tumor tissue sections 
as described [24, 41, 43]. Antibodies used were, anti-
βIII-tubulin (1:200) (Chemicon), anti-βII-tubulin (1:200) 
(Covance), anti-luciferase (1:50) (Biovision incorporated). 
siRNA transfection 
Pancreatic cancer cells and HPDE cells were 
transfected with siRNAs using Lipofectamine 2000 
(Invitrogen). All cells were transfected with smart pool 
On-Target Plus siRNAs designed against βII-Tubulin 
(Thermoscientific, Cat. L-008260-00), βIII-Tubulin 
(Thermoscientific, Cat. L-020099-00), or non-silencing 
control (Thermoscientific, Cat. D-001810-10-20). 
Real time quantitative PCR (qPCR) 
Total RNA was extracted from pancreatic cancer 
cells and HPDEs, and transcribed to cDNA as described 
[24, 43]. qPCR was performed using the QuantiFast 
SYBR Green PCR kit (Qiagen) as described [24, 43]. 
Primer sequences were: βIII-Tubulin forward primer, 
5′-GCGAGATGTACGAAGACGAC-3′; βIII-Tubulin 
reverse primer, 5′-TTTAGACACTGCTGGCTTCG-3′; 
βII-Tubulin forward primer, 
5′-AAAGAATTCGACGCCACGGCCGACGAA 
CAAGGG-3′; βII-Tubulin reverse primer, 
5′-AAAAGCTTACAAACGTTTATGTGATTTTAG-3′. 
All data were normalized to the 18S gene (Quantitect 
Primer Assay, Qiagen).
Western blot analysis
Western blot analysis was performed using the 
following antibodies: anti-βIII-tubulin (Chemicon), anti-
βII-tubulin (Covance), anti-βI-tubulin (Covance) and 
anti-GAPDH (Abcam) as described [22, 24, 28]. The 
blots were scanned using LAS4000 scanner and quantified 
using ImageQuant TL (GE Healthcare). 
Immunofluorescence staining
24h post-transfection with siRNA, cells were seeded 
onto glass chamber slides and allowed to adhere for 
48h. The slides were fixed in 4% paraformaldehyde and 
immunofluorescence staining was performed as described 
[22, 43, 44]. Primary and secondary antibodies used were, 
anti-βIII-tubulin (1:500), anti-α-tubulin (1:500), anti-goat 
AlexaFluor-488 or AlexaFluor-555 (1:1000). Images were 
captured using a Leica confocal microscope.
Cell proliferation assays
HPDE cell proliferation was measured 72h post-
transfection using the Cell Counting Kit-8 (CCK-8) kit 
(Dojindo) as described [24, 41]. MiaPaCa-2 proliferation 
was measured on an xCELLigence platform (ACEA 
Biosciences). Cells were seeded 72h post-transfection at 
3000 cells/well into 96-well E-Plates (ACEA Biosciences), 
then transferred into an xCELLigence in a humidified 
37oC chamber in 5% CO2. Cell Index (Proliferation) was 
measured hourly for 48h.
Cytotoxic drug-clonogenic assays 
Following siRNA transfection cytotoxic drug-
clonogenic assays were performed as described [22, 24, 
28]. 
Cell cycle analysis
72h post siRNA transfection, MiaPaCa-2 cells were 
incubated in Taxol (0-40 nM) or Vincristine (0-10 nM) for 
8h, and cell cycle measured as described [44]. 
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Detection of apoptosis 
48h after siRNA transfection, pancreatic cancer cells 
were treated with culture medium containing cytotoxic 
drugs for 24h. Cell death was measured using the Annexin 
V-PE-7-AAD-FITC reagent (Millipore) as described 
[41, 45, 46]. Caspase 3/7 activity was analyzed using 
a Caspase-Glo luminescent based assay as previously 
described [24, 41]. Briefly, pancreatic cancer cells were 
treated with siRNA as above and seeded into a 96-well 
white opaque plate and a corresponding clear 96-well 
plate. 24h post-cytotoxic drug treatment, cells in the white 
opaque plate were incubated with caspase 3/7 reagent for 
2h at room temperature and luminescence measured with 
a luminometer (PerkinElmer Victor 3). Cells in the clear 
96-well plate were incubated with CCK-8 reagent for 1h 
at room temperature and cell viability was determined by 
measuring absorbance at 450nm. Caspase 3/7 activity was 
then normalized to these values. 
Soft-agar assay 
MiaPaCa-2 and HPAF-II cells were seeded in 
0.33% agar in X2 growth medium on a 5% agar layer 
in 6 well plates, 48h post-siRNA transfection. Colonies 
were allowed to grow over 3 weeks, after which plates 
were stained with MTT and visualized on an ImageQuant 
LAS4000 luminometer (GE Healthcare). Colonies were 
counted as described [24]. 
Anoikis assay
1 ml of 12 mg/ml poly 2-hyroxyethyl methacrylate 
(Poly-HEMA) in 95% ethanol was added into each well of 
a 6-well culture plate and left to dry overnight. 24h after 
siRNA transfection MiaPaCa-2 cells were seeded into the 
Poly-HEMA-coated wells. Cell death was measured 48h 
later by annexin V-7AAD staining. 
Generation of βIII-tubulin stable short hairpin 
RNA (shRNA)–luciferase expressing cells
MiaPaCa-2 cells were first transfected with 2 
µg of pGL4.50 (Mammalian Luciferase, Promega) 
using lipofectamine 2000. Clones with stable 
integration of the construct were isolated. A stable 
luciferase-expressing line was transfected with 2 
µg of pGFP-V-RS empty vector (negative control), 
pGFP-V-RS vector containing βIII-tubulin shRNA 
(5′-CAGCAGATGTTCGATGCCAAGAACATGAT-3′) 
or pGFP-V-RS vector containing a non-effective shRNA 
(5′-GCACTACCAGAGCTAACTCAGATAGTACT-3′) 
(OriGENE) using lipofectamine 2000. Three days after 
transfection, the integration of the shRNA plasmid was 
verified by measuring βIII-tubulin expression. GFPhi cells 
were sorted on a BD Influx Cell Sorter and propagated for 
2 weeks in 1 µg/ml puromycin. 
Orthotopic pancreatic cancer mouse model 
6-8 week old BALB/c nude mice were used. All 
animal experiments were approved by the Animal Ethics 
committee, UNSW (ACEC 12/7B). MiaPaCa-2 cells 
(1X106) were implanted into the tail of the pancreas of 
mice as described [41, 46]. After 8 weeks, mice were 
sacrificed and pancreatic tumors, spleen, liver, kidneys, 
Intestines, heart and lungs and any enlarged lymph nodes/
other organs with signs of metastases were collected. 
Primary tumor size was measured using microcallipers 
as described [24, 43]. Metastases were confirmed by 
macroscopic observation, post-harvest individual organ 
ex-vivo bioluminescence on the Xenogen IVIS Lumina, 
as described [47]. 
Statistical Analyses 
Data are expressed as mean ± standard error of 
the mean (SEM) and analyzed where appropriate using 
ANOVA followed by parametric Dunnett, or Student’s t 
test followed by the nonparametric Wilcoxin test using 
the GraphPad Prism program. P<0.05 was considered 
statistically significant.
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